Literature DB >> 17486648

Role of DAT-SPECT in the diagnostic work up of parkinsonism.

Christoph Scherfler1, Johannes Schwarz, Angelo Antonini, Donald Grosset, Francesc Valldeoriola, Kenneth Marek, Wolfgang Oertel, Eduardo Tolosa, Andrew J Lees, Werner Poewe.   

Abstract

The diagnosis of idiopathic Parkinson's disease (PD) can be achieved with high degrees of accuracy in cases with full expression of classical clinical features. However, diagnostic uncertainty remains in early disease with subtle or ambiguous signs. Functional imaging has been suggested to increase the diagnostic yield in parkinsonian syndromes with uncertain clinical classification. Loss of striatal dopamine nerve terminal function, a hallmark of neurodegenerative parkinsonism, is strongly related to decreases of dopamine transporter (DAT) density, which can be measured by single photon emission computed tomography (SPECT). The use of DAT-SPECT facilitates the differential diagnosis in patients with isolated tremor symptoms not fulfilling PD or essential tremor criteria, drug-induced, psychogenic and vascular parkinsonism as well as dementia when associated with parkinsonism. This review addresses the value of DAT-SPECT in early differential diagnosis, and its potential as a screening tool for subjects at risk of developing PD as well as issues around the assessment of disease progression. 2007 Movement Disorder Society

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17486648     DOI: 10.1002/mds.21505

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  49 in total

Review 1.  Physiology of psychogenic movement disorders.

Authors:  Mark Hallett
Journal:  J Clin Neurosci       Date:  2010-05-20       Impact factor: 1.961

2.  Psychogenic movement disorders.

Authors:  Elizabeth L Peckham; Mark Hallett
Journal:  Neurol Clin       Date:  2009-08       Impact factor: 3.806

Review 3.  Epidemiology of Parkinson's disease.

Authors:  Guido Alves; Elin Bjelland Forsaa; Kenn Freddy Pedersen; Michaela Dreetz Gjerstad; Jan Petter Larsen
Journal:  J Neurol       Date:  2008-09       Impact factor: 4.849

Review 4.  Clinical use of dopamine transporter imaging in movement disorders: benefits of appropriate use.

Authors:  Giovanni Lucignani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-06       Impact factor: 9.236

5.  An exploration of ocular fixation in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.

Authors:  Ralph Allen Pinnock; Richard Canice McGivern; Raeburn Forbes; James Mark Gibson
Journal:  J Neurol       Date:  2009-10-22       Impact factor: 4.849

6.  CSF xanthine, homovanillic acid, and their ratio as biomarkers of Parkinson's disease.

Authors:  Peter LeWitt; Lonni Schultz; Peggy Auinger; Mei Lu
Journal:  Brain Res       Date:  2011-07-01       Impact factor: 3.252

7.  Pre- and postsynaptic dopamine SPECT in the early phase of idiopathic parkinsonism: a population-based study.

Authors:  Susanna Jakobson Mo; Jan Linder; Lars Forsgren; Anne Larsson; Lennart Johansson; Katrine Riklund
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-07-01       Impact factor: 9.236

Review 8.  Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.

Authors:  Fanni F Geibl; Martin T Henrich; Wolfgang H Oertel
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

9.  EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2.

Authors:  Jacques Darcourt; Jan Booij; Klaus Tatsch; Andrea Varrone; Thierry Vander Borght; Ozlem L Kapucu; Kjell Någren; Flavio Nobili; Zuzana Walker; Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-02       Impact factor: 9.236

10.  The role of I-ioflupane SPECT dopamine transporter imaging in the diagnosis and treatment of patients with dementia with Lewy bodies.

Authors:  Angelo Antonini
Journal:  Neuropsychiatr Dis Treat       Date:  2007-06       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.